Cosentyx® (secukinumab)

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.¹

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.¹

In Ireland Cosentyx is reimbursed for the following indications: adult plaque psoriasis (PsO); psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

Please refer to the Summary of Product Characteristics (SmPC) for full prescribing information and safety profile.¹

Cosentyx is the FIRST biologic with proven efficacy in all six manifestations^1–7

Key clinical manifestations of PsA are joint, axial, skin, enthesitis, dactylitis and nails.⁵

All the primary endpoints were met in the studies referenced above.^3,5–7

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information before prescribing.¹

*ULTIMATE: Observed data in biologic-naïve patients with PsA receiving Cosentyx 300 mg or 150 mg who were originally randomly assigned to Cosentyx (n=83).^6
†FUTURE 2: Observed data for the 150-mg treatment group of biologic-naïve patients with PsO affecting 3% or more of body surface area at baseline including those originally randomly assigned to Cosentyx and placebo-switchers (n=42); 64% in the respective 300-mg group maintained PASI 90 through Year 5 (n=28).^3
‡TRANSFIGURE: Observed data in patients with moderate to severe nail PsO in the Cosentyx 300 mg treatment group (n=66; NRI; observed data).^7
§MAXIMISE: Observed data in biologic-naïve patients with PsA in the Cosentyx 300 mg treatment group (n=139); in the respective Cosentyx 150 mg treatment group, 65% achieved ASAS40 at Year 1 (n=141).^5

¶FUTURE 2: Observed data for the Cosentyx 300 mg treatment group of biologic-naïve patients with this symptom at baseline, including those originally randomly assigned to Cosentyx and placebo-switchers (n=31); 86% in the respective Cosentyx 150 mg group maintained complete resolution of dactylitis through Year 5 (n=22).^3
‖FUTURE 2: Observed data for the Cosentyx 300 mg treatment group of biologic-naïve patients with this symptom at baseline, including those originally randomly assigned to Cosentyx and placebo-switchers (n=36); 76% in the respective Cosentyx 150 mg group maintained complete resolution of enthesitis through Year 5 (n=45).³

ACR, American College of Rheumatology; AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; axSpA, axial spondyloarthritis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; JIA, juvenile idiopathic arthritis; JPsA, juvenile psoriatic arthritis; mNAPSI, modified nail psoriasis severity index; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; NRI, non-responder imputation; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC,summary of product characteristics.

References

1. Cosentyx® (secukinumab) Summary of Product Characteristics. Available at www.medicines.ie.

2. Baraliakos X, et al. Ann Rheum Dis 2020;0:1–9.

3. McInnes IB, et al. Lancet Rheumatol 2020;2(4):e227-e235 and supplementary appendix.

4. Mease PJ, et al. ACR Open Rheumatol 2020 Jan;2(1):18–25.

5. Baraliakos X, et al. Ann Rheum Dis 2021;80(5):582–590.

6. D’Agostino MA, et al. Semin Arthritis Rheum 2023;63:152259 and supplementary appendix.

7. Reich K, et al. Br J Dermatol 2021;184(3):425–436.

IE11533962 | March 2026